No Data
No Data
Zai Lab's AUGTYRO For ROS1+ NSCLC Added To China's National Reimbursement Drug List
Express News | Zai Lab Announces the Inclusion of Augtyro® (Repotrectinib) for Ros1+ Nsclc and Other Updates in China’s National Reimbursement Drug List
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading
Zai Lab Raises $216 Million Through ADS Offering
Hong Kong stocks fluctuate | Zai Lab (09688) rises over 5% as it cooperates with Pfizer on the new antibacterial drug in mainland China.
zai lab (09688) rose more than 5%, as of the deadline, it increased by 5.26%, closing at 20.8 Hong Kong dollars, with a turnover of 7.8692 million Hong Kong dollars.
Zai Lab (09688.HK) has completed the offering of American depositary shares and the full exercise of options.
Grantham 22nd November News: zai lab (09688.HK) announced with pleasure that on 18th November 2024 (USA Eastern Time), it completed the public offering of 7,843,137 American Depositary Shares at a price of $25.50 per ADS (equivalent to approximately HK$19.84 per share (calculated based on the ratio of one ADS to every ten shares)). In addition, the underwriters have fully exercised their options to purchase an additional 1,176,470 ADS at the offer price minus the underwriting discount and commissions. Regarding the options of American Depositary Shares.
No Data
No Data
Methods : and yet it's red!
Stock_Drift OP Methods : Red is making its rounds this morning, I’ll agree with that.
Methods Stock_Drift OP : No this is always red.. 24.5 seems to be strong support though
Stock_Drift OP Methods : Fair enough